Considerations for generic oncology FDG-PET/CT protocol preparation in drug development

IDrugs. 2007 Nov;10(11):791-6.


[18F]Fluorodeoxyglucose (FDG)-PET combined with CT is increasingly being used as an imaging tool in oncology clinical trials. Progress in the standardization and harmonization of acquisition and analysis protocols for FDG-PET/CT has been made, although there are still areas for which further guidance is needed. Standardizing FDG-PET/CT clinical trial design and interpretation will contribute to increased efficiency and precision in decision-making for drug development. This feature review highlights areas in FDG-PET/CT imaging, particularly image analysis and response classification, that currently require expert guidance or further research to optimize the application of this tool in oncological drug development.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic / standards
  • Drug Design
  • Fluorodeoxyglucose F18*
  • Humans
  • Models, Statistical
  • Neoplasms / diagnosis*
  • Patient Selection
  • Positron-Emission Tomography / instrumentation
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals*
  • Research Design / standards
  • Tomography, X-Ray Computed / instrumentation
  • Tomography, X-Ray Computed / methods*


  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18